SAN FRANCISCO: Heather Cheng was very much in favour of using enzalutamide after abiraterone since her data show a 30 per cent response rate even in a third of patients who had not responded at all to abi, and higher proportions in both abi-responders and abi-naïve patients. She believed this indicates non-cross-resistance between these two agents.
Heather H Cheng MD PhD, Fred Hutchinson Cancer Research Center
“The effect of prior abiraterone (Abi) use on the activity of enzalutamide (Enza) in men with mCRPC.”
ASCO 2014 Genitourinary Cancers Symposium